Northeast Financial Consultants Inc Biocryst Pharmaceuticals Inc Transaction History
Northeast Financial Consultants Inc
- $2.02 Billion
- Q1 2024
A detailed history of Northeast Financial Consultants Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Northeast Financial Consultants Inc holds 60,633 shares of BCRX stock, worth $397,146. This represents 0.02% of its overall portfolio holdings.
Number of Shares
60,633
Previous 60,633
-0.0%
Holding current value
$397,146
Previous $363,000
15.15%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding BCRX
# of Institutions
256Shares Held
182MCall Options Held
839KPut Options Held
816K-
Black Rock Inc. New York, NY18.4MShares$121 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.7MShares$116 Million0.0% of portfolio
-
State Street Corp Boston, MA17.5MShares$114 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY13.1MShares$85.5 Million0.8% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$66.3 Million0.65% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.22B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...